| 01.10 13:05 | dpa-AFX: *ASTRAZENECA AND DAIICHI SANKYO:ENHERTU GRANTED PRIORITY REVIEW IN US FOR HER2-LOW/HER2-ULTRALOW METASTATIC BREAST CANCER |
| 01.10 08:29 | dpa-AFX: Daiichi Says Enhertu Gets Priority Review In US In HER2 Low/HER2 Ultralow Metastatic Breast Cancer |
| 17.09 12:45 | dpa-AFX: Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study |
| 17.09 12:08 | dpa-AFX: *DAIICHI SANKYO AND MERCK: HERTHENA-LUNG02 PHASE 3 TRIAL OF PATRITUMAB MEETS PRIMARY ENDPOINT |
| 10.09 09:18 | MÄRKTE ASIEN/Uneinheitlich - Anleger halten sich vor US-Daten zurück |
| 10.09 03:43 | dpa-AFX: AstraZeneca :Dato-DXd Fails To Significantly Improve Overall Survival In Phase III Lung Cancer Trial |
| 08.09 04:49 | dpa-AFX: Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial |
| 19.08 08:39 | dpa-AFX: AZN: Enhertu Gets US Breakthrough Therapy Designation For HER2 Low/Ultralow Metastatic Breast Cancer |
| 19.08 08:14 | dpa-AFX: *DAIICHI SANKYO : ENHERTU GETS U.S. BREAKTHROUGH THERAPY DESIGNATION FOR HER2 LOW AND ULTRALOW METASTATIC BREAST CANCER |
| 06.08 14:11 | dpa-AFX: Daiichi Sankyo, Merck Expand Partnership To Include Merck's MK-6070 |
| 06.08 12:48 | dpa-AFX: *DAIICHI SANKYO AND MERCK ENTER GLOBAL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR MK-6070 |
| 01.08 14:09 | dpa-AFX: *MERCK DOSES FIRST PATIENT IN IDEATE-LUNG02 PHASE 3 TRIAL OF IFINATAMAB DERUXTECAN IN RELAPSED SMALL CELL LUNG CANCER |
| 30.07 11:23 | Englische Behörde findet Astrazenecas Brustkrebsmittel Enhertu zu teuer |
| 27.06 02:36 | dpa-AFX: Merck : FDA Issues Complete Response Letter For Patritumab Deruxtecan In EGFR-Mutated NSCLC |
| 27.05 08:34 | dpa-AFX: AZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical Significance |
| 29.04 08:30 | dpa-AFX: AstraZeneca: Enhertu Improved PFS In HR-positive, HER2-low Metastatic Breast Cancer |
| 10.04 07:15 | dpa-AFX: Roche Gets CE Mark For First Companion Diagnostic To Identify HER2-low Metastatic Breast Cancer |
| 06.04 04:02 | dpa-AFX: FDA Approves AstraZeneca And Daiichi Sankyo's Enhertu For Solid Tumors Treatment |
| 02.04 08:04 | dpa-AFX: *ASTRAZENECA AND DAIICHI SANKYO: FDA ACCEPTS DATOPOTAMAB DERUXTECAN BLA FOR BREAST CANCER |
| 04.03 08:41 | EU gibt Astrazeneca zwei Zulassungen für neues Krebsmedikament |
|
|
